WuXi AppTec Co., Ltd. (WUXAY)
OTCMKTS · Delayed Price · Currency is USD
15.02
-0.41 (-2.66%)
Oct 9, 2025, 3:58 PM EDT
WuXi AppTec Revenue
WuXi AppTec had revenue of 41.90B CNY in the twelve months ending June 30, 2025, up 15.64% year-over-year. In the year 2024, WuXi AppTec had annual revenue of 37.92B, down -1.97%.
Revenue (ttm)
41.90B CNY
Revenue Growth
+15.64%
P/S Ratio
7.93
Revenue / Employee
1.06M CNY
Employees
39,414
Market Cap
46.40B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.92B | -760.22M | -1.97% |
| Dec 31, 2023 | 38.68B | -676.78M | -1.72% |
| Dec 31, 2022 | 39.35B | 16.45B | 71.84% |
| Dec 31, 2021 | 22.90B | 6.37B | 38.50% |
| Dec 31, 2020 | 16.54B | 3.66B | 28.46% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Elite Pharmaceuticals | 105.45M |
| Glass House Brands | 221.55M |
| Veradigm | 588.02M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| Jushi Holdings | 256.36M |
| AMJ Global Technology | 39.00 |
WuXi AppTec News
- 18 days ago - WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends - PRNewsWire
- 4 weeks ago - WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year - PRNewsWire
- 6 weeks ago - WuXi AppTec Completes Second RMB1.0 Billion A-Share Repurchase Program in 2025, All Repurchased Shares to Be Cancelled - PRNewsWire
- 2 months ago - WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year - PRNewsWire
- 2 months ago - China's Wuxi Apptec to raise over $980 million to boost expansion - Reuters
- 2 months ago - WuXi AppTec Co., Ltd. (WUXIF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - WuXi AppTec Achieves Strong Growth in Revenue and Profit for Q2 and H1 2025, H1 Revenue from Continuing Operations[1] Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY; Backlog for Continuing Operations Up 37.2% YoY - PRNewsWire
- 3 months ago - WuXi AppTec Issues Positive Profit Alert for the First Half of 2025 - PRNewsWire